This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quinn, D. I. Articles by Stricker, P. D. Search for Related Content PubMed PubMed Citation Articles by Quinn, D. I. Articles by Stricker, P. D.

Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models

From the Cancer Research Program, Garvan Institute of Medical Research and Departments of Urology, Anatomical Pathology, and Medical Oncology, St Vincent’s Hospital, Darlinghurst; and Douglass Hanly Moir Pathology and Sydney Diagnostic Services, North Ryde, Australia.

Address correspondence to Phillip D. Stricker, MD, Department of Urology, St Vincent’s Clinic, Victoria St, Darlinghurst, New South Wales 2010, Australia; email: stricker{at}ozemail.com.au

PURPOSE: Although predicting outcome for men with clinically localized prostate cancer (PC) has improved, the staging system and nomograms used to do this are based on results from the North American health system. To be internationally applicable, these models require testing in cohorts from a variety of different health systems based on the predominant PC case identification methods used.

PATIENTS AND METHODS: We studied 732 men with localized PC treated with radical prostatectomy and no preoperative therapy between 1986 and 1999 at one Australian institution to determine the effect of clinicopathologic features on disease-free survival.

RESULTS: Preoperative serum prostate-specific antigen (PSA) concentration, Gleason score, pathologic stage, and year of surgery were independent predictors of outcome. Although margin status demonstrated only a trend toward significance in multivariate modeling overall, it proved to be independent in subgroups based on later year of surgery (1986 to 1994 v 1995 to 1998), preoperative PSA of less than 10 ng/mL, and Gleason score 7. Adjuvant radiation therapy improved disease-free survival rates in patients with multiple surgical margin involvement.

CONCLUSION: This work confirms the prognostic significance of pathologic stage, Gleason score, and preoperative serum PSA. In the context of a contemporaneous screening effect in Australia, these findings may have implications for methods that predict outcome following surgery as screening becomes more prevalent in a population. The independent prognostic effect of margin status may alter with an increase in the proportion of screening-identified PCs. Staging systems and nomograms that predict outcome following surgery require validation in cohorts with different health practices before being universally applied.

This article has been cited by other articles:

				S. M. Henshall, L. G. Horvath, D. I. Quinn, S. A. Eggleton, J. J. Grygiel, P. D. Stricker, A. V. Biankin, J. G. Kench, and R. L. Sutherland Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst, October 4, 2006; 98(19): 1420 - 1424. [Abstract] [Full Text] [PDF]

				K. K. Rasiah, J. G. Kench, M. Gardiner-Garden, A. V. Biankin, D. Golovsky, P. C. Brenner, R. Kooner, G. F. O'Neill, J. J. Turner, W. Delprado, et al. Aberrant neuropeptide y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 711 - 716. [Abstract] [Full Text] [PDF]

				G. Xia, S. R. Kumar, R. Masood, S. Zhu, R. Reddy, V. Krasnoperov, D. I. Quinn, S. M. Henshall, R. L. Sutherland, J. K. Pinski, et al. EphB4 Expression and Biological Significance in Prostate Cancer Cancer Res., June 1, 2005; 65(11): 4623 - 4632. [Abstract] [Full Text] [PDF]

				A. R. Bauskin, D. A. Brown, S. Junankar, K. K. Rasiah, S. Eggleton, M. Hunter, T. Liu, D. Smith, T. Kuffner, G. J. Pankhurst, et al. The Propeptide Mediates Formation of Stromal Stores of PROMIC-1: Role in Determining Prostate Cancer Outcome Cancer Res., March 15, 2005; 65(6): 2330 - 2336. [Abstract] [Full Text] [PDF]

				L. G. Horvath, S. M. Henshall, J. G. Kench, D. N. Saunders, C.-S. Lee, D. Golovsky, P. C. Brenner, G. F. O'Neill, R. Kooner, P. D. Stricker, et al. Membranous Expression of Secreted Frizzled-Related Protein 4 Predicts for Good Prognosis in Localized Prostate Cancer and Inhibits PC3 Cellular Proliferation in Vitro Clin. Cancer Res., January 15, 2004; 10(2): 615 - 625. [Abstract] [Full Text] [PDF]

				H. Augustin, M. Graefen, J. Palisaar, J. Blonski, A. Erbersdobler, F. Daghofer, H. Huland, and P. G. Hammerer Prognostic Significance of Visible Lesions on Transrectal Ultrasound in Impalpable Prostate Cancers: Implications for Staging J. Clin. Oncol., August 1, 2003; 21(15): 2860 - 2868. [Abstract] [Full Text] [PDF]

				S. M. Henshall, D. E. H. Afar, J. Hiller, L. G. Horvath, D. I. Quinn, K. K. Rasiah, K. Gish, D. Willhite, J. G. Kench, M. Gardiner-Garden, et al. Survival Analysis of Genome-Wide Gene Expression Profiles of Prostate Cancers Identifies New Prognostic Targets of Disease Relapse Cancer Res., July 15, 2003; 63(14): 4196 - 4203. [Abstract] [Full Text] [PDF]